NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
Phase 1
Completed
- Conditions
- Recurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT00138177
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Stage IV Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00138203
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Gundersen Lutheran, La Crosse, Wisconsin, United States
🇺🇸Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- Drug: LADR Treatment
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2013-04-23
- Target Recruit Count
- 79
- Registration Number
- NCT00135798
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
Phase 3
Completed
- Conditions
- Glomerulosclerosis, Focal
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2012-05-22
- Target Recruit Count
- 207
- Registration Number
- NCT00135811
- Locations
- 🇺🇸
Data Coordinating Center; Cleveland Clinic Foundation; Quantitative Health Sciences; 9500 Euclid Avenue, Cleveland, Ohio, United States
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Stage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage III Colon Cancer
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00134069
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Colorado at Denver Health Sciences Center, Aurora, Colorado, United States
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
Phase 2
Completed
- Conditions
- Stage IV Follicular Thyroid CancerStage II Follicular Thyroid CancerInsular Thyroid CancerRecurrent Thyroid CancerThyroid Gland Medullary CarcinomaStage II Papillary Thyroid CancerStage IV Papillary Thyroid Cancer
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00134043
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT00131937
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Adult Favorable Prognosis Hodgkin LymphomaAdult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Nodular Lymphocyte Predominant Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaAdult Unfavorable Prognosis Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaRecurrent Adult Hodgkin Lymphoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00132028
- Locations
- 🇺🇸
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
Phase 2
Terminated
- Conditions
- Male Breast CancerStage IV Breast CancerRecurrent Breast Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT00132002
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Phase 2
Completed
- Conditions
- Recurrent Gastrointestinal Carcinoid TumorGastrinomaNeuroendocrine TumorPancreatic Polypeptide TumorSomatostatinomaGlucagonomaMetastatic Gastrointestinal Carcinoid TumorWDHA SyndromeInsulinomaRecurrent Islet Cell Carcinoma
- Interventions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 93
- Registration Number
- NCT00131911
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States